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Heterosexual RAI is common, with rates from 5–10% in
the general population of women with up to 30–50%
among women with other risk for HIV infection. RAI is
considered to be the most common route of HIV trans-
mission in men who have sex with men (MSM). Because
of this broad and continuing HIV risk, topical HIV rectal
microbicides are being developed to prevent rectal sexual
transmission of HIV.
The environment of the rectosigmoid region of the colon
is very different to the vagina, serving different physiolog-
ical roles and, as a consequence, have unique and distinct
features that complicate microbicide development. In
contrast to the robust, stratified squamous, epithelium
lining the vagina, the intestinal mucosa is lined by a single
layer of columnar epithelium that is very vulnerable to
trauma or potential microbicide toxicity. Moreover, the
gut associated lymphoid tissue (GALT), underlying the
mucosal surface, has a physiological level of inflamma-
tion perfectly suited to HIV replication. The limited ana-
tomical space of the vaginal cavity contrasts with the
relative enormity of the intestinal colon and raises pro-
found questions about drug delivery and distribution.
Despite these significant challenges, recent animal studies
have shown the feasibility of preventing rectal SIV trans-
mission using a locally applied microbicide.
Collaborative efforts are underway to begin to address
these divergent needs in developing a safe rectal microbi-
cide (RM). These include a recently concluded trial defin-
ing safety parameters (HPTN 056) and a focused NIH
U19, now ending Year 1, with a targeted 5-year goal of ini-
tiating Phase 1 RM study. Failure to acknowledge the role
that RAI plays in the global AIDS pandemic is likely to
limit the success of intervention strategies and, more spe-
cifically, compromise attempts to develop safe and effec-
tive vaginal microbicides.
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